Back to Search Start Over

A novel sequencing-based vaginal health assay combining self-sampling, HPV detection and genotyping, STI detection, and vaginal microbiome analysis.

Authors :
Elisabeth M Bik
Sara W Bird
Juan P Bustamante
Luis E Leon
Pamela A Nieto
Kwasi Addae
Víctor Alegría-Mera
Cristian Bravo
Denisse Bravo
Juan P Cardenas
Glenn A Carson
Adam Caughey
Paulo C Covarrubias
José Pérez-Donoso
Graham Gass
Sarah L Gupta
Kira Harman
Donna Marie B Hongo
Juan C Jiménez
Laurens Kraal
Felipe Melis-Arcos
Eduardo H Morales
Amanda Morton
Camila F Navas
Harold Nuñez
Eduardo Olivares
Nicolás Órdenes-Aenishanslins
Francisco J Ossandon
Richard Phan
Raul Pino
Katia Soto-Liebe
Ignacio Varas
Patricia Vera-Wolf
Nathaniel A Walton
Daniel E Almonacid
Audrey D Goddard
Juan A Ugalde
Susan Zneimer
Jessica Richman
Zachary S Apte
Source :
PLoS ONE, Vol 14, Iss 5, p e0215945 (2019)
Publication Year :
2019
Publisher :
Public Library of Science (PLoS), 2019.

Abstract

The composition of the vaginal microbiome, including both the presence of pathogens involved in sexually transmitted infections (STI) as well as commensal microbiota, has been shown to have important associations for a woman's reproductive and general health. Currently, healthcare providers cannot offer comprehensive vaginal microbiome screening, but are limited to the detection of individual pathogens, such as high-risk human papillomavirus (hrHPV), the predominant cause of cervical cancer. There is no single test on the market that combines HPV, STI, and microbiome screening. Here, we describe a novel inclusive vaginal health assay that combines self-sampling with sequencing-based HPV detection and genotyping, vaginal microbiome analysis, and STI-associated pathogen detection. The assay includes genotyping and detection of 14 hrHPV types, 5 low-risk HPV types (lrHPV), as well as the relative abundance of 31 bacterial taxa of clinical importance, including Lactobacillus, Sneathia, Gardnerella, and 3 pathogens involved in STI, with high sensitivity, specificity, and reproducibility. For each of these taxa, reference ranges were determined in a group of 50 self-reported healthy women. The HPV sequencing portion of the test was evaluated against the digene High-Risk HPV HC2 DNA test. For hrHPV genotyping, agreement was 95.3% with a kappa of 0.804 (601 samples); after removal of samples in which the digene hrHPV probe showed cross-reactivity with lrHPV types, the sensitivity and specificity of the hrHPV genotyping assay were 94.5% and 96.6%, respectively, with a kappa of 0.841. For lrHPV genotyping, agreement was 93.9% with a kappa of 0.788 (148 samples), while sensitivity and specificity were 100% and 92.9%, respectively. This novel assay could be used to complement conventional cervical cancer screening, because its self-sampling format can expand access among women who would otherwise not participate, and because of its additional information about the composition of the vaginal microbiome and the presence of pathogens.

Subjects

Subjects :
Medicine
Science

Details

Language :
English
ISSN :
19326203
Volume :
14
Issue :
5
Database :
Directory of Open Access Journals
Journal :
PLoS ONE
Publication Type :
Academic Journal
Accession number :
edsdoj.5898905ae8a940088488e6ace215245f
Document Type :
article
Full Text :
https://doi.org/10.1371/journal.pone.0215945